LAVAL, QC and LYON, France, Nov. 29, 2016 /PRNewswire/ - Accinov of Lyon, France, and Biodextris of Laval, QC, Canada, are pleased to announce the signing of a co-marketing agreement, presenting customers with an alternative to traditional contract development and manufacturing organizations (CDMO) for the development, production and testing of biopharmaceutical products.
(Photo: http://photos.prnewswire.com/prnh/20161125/442978LOGO)
Under the terms of the non-exclusive co-operative agreement, the two companies will work together to co-promote their complementary services to clients in Europe, North America and beyond.
Accinov will be able to present clients to Biodextris' process development, analytical development and cGMP QC testing services, while Biodextris can introduce clients to Accinov's flexible, ready-to-use cGMP biomanufacturing environment and associated quality assurance services.
Clients will benefit from a seamless customer experience thanks to the coordinated approach, aligned expertise and shared focus on delivering integrated solutions for clients developing innovative biologic products.
"We are excited to enter this agreement with Accinov, who are pioneering a biomanufacturing model unique in the pharmaceutical and biotechnology industries," said Joseph Zimmermann, Biodextris President and CEO, "This strategic collaboration reflects our commitment to providing a full-spectrum service offering and broadening the competitive advantage customers realize working with our organizations".
"The Biodextris team's history of advancing vaccine and biologic products to the clinic and the Accinov team's expertise are complementary and self-reinforcing" said André Dupont, Accinov President "Together we establish a wholly flexible solution for the development & GMP manufacturing of new biopharmaceuticals."
About Accinov
Accinov is a biomanufacturing center and provides biotech, pharma and medtech companies with state of the art R&D laboratories (BSL2), cleanrooms (ISO 8-7), GMP manufacturing pilot units & tailored solutions for quality assurance & pharmaceutical support to boost their projects, keep internally their know-how and their IP & manage their facilities in the most flexible way.Accinov's customers have just to plug their projects & play in a full ISO/GMP compliant environment.Accinov has had pharmaceutical establishment status since September 2014 and hosts more than 15 companies and projects, including experimental new drugs production projects.Accinov is part of the infrastructure of Lyonbiopôle, the biocluster of the Rhône-Alpes region and is located in Lyon in the heart of the Lyon Gerland Biodistrict.
For more information: www.accinov.com Follow us on Twitter : @Accinov Follow us on Linkedin : www.linkedin.com/company/accinov
Contact: Stéphanie Colloud, CEO Tel: +33-(0)4-3728-7300 Email: [email protected]
About Biodextris
Biodextris is a Canadian contract research organization providing a suite of analytical, process development and CMC consulting services for vaccines and biologics in the clinical stages of development. The company's expertise, facilities and quality systems support clients to confidently navigate a path from R&D to early-phase clinical trials. For more information, visit: www.biodextris.com.
SOURCE biodextris
Advertisement
(Photo: http://photos.prnewswire.com/prnh/20161125/442978LOGO)
Under the terms of the non-exclusive co-operative agreement, the two companies will work together to co-promote their complementary services to clients in Europe, North America and beyond.
Advertisement
Accinov will be able to present clients to Biodextris' process development, analytical development and cGMP QC testing services, while Biodextris can introduce clients to Accinov's flexible, ready-to-use cGMP biomanufacturing environment and associated quality assurance services.
Clients will benefit from a seamless customer experience thanks to the coordinated approach, aligned expertise and shared focus on delivering integrated solutions for clients developing innovative biologic products.
"We are excited to enter this agreement with Accinov, who are pioneering a biomanufacturing model unique in the pharmaceutical and biotechnology industries," said Joseph Zimmermann, Biodextris President and CEO, "This strategic collaboration reflects our commitment to providing a full-spectrum service offering and broadening the competitive advantage customers realize working with our organizations".
"The Biodextris team's history of advancing vaccine and biologic products to the clinic and the Accinov team's expertise are complementary and self-reinforcing" said André Dupont, Accinov President "Together we establish a wholly flexible solution for the development & GMP manufacturing of new biopharmaceuticals."
About Accinov
Accinov is a biomanufacturing center and provides biotech, pharma and medtech companies with state of the art R&D laboratories (BSL2), cleanrooms (ISO 8-7), GMP manufacturing pilot units & tailored solutions for quality assurance & pharmaceutical support to boost their projects, keep internally their know-how and their IP & manage their facilities in the most flexible way.Accinov's customers have just to plug their projects & play in a full ISO/GMP compliant environment.Accinov has had pharmaceutical establishment status since September 2014 and hosts more than 15 companies and projects, including experimental new drugs production projects.Accinov is part of the infrastructure of Lyonbiopôle, the biocluster of the Rhône-Alpes region and is located in Lyon in the heart of the Lyon Gerland Biodistrict.
For more information: www.accinov.com Follow us on Twitter : @Accinov Follow us on Linkedin : www.linkedin.com/company/accinov
Contact: Stéphanie Colloud, CEO Tel: +33-(0)4-3728-7300 Email: [email protected]
About Biodextris
Biodextris is a Canadian contract research organization providing a suite of analytical, process development and CMC consulting services for vaccines and biologics in the clinical stages of development. The company's expertise, facilities and quality systems support clients to confidently navigate a path from R&D to early-phase clinical trials. For more information, visit: www.biodextris.com.
SOURCE biodextris
